Reappraisal of Antihypertensive Medicine Doxazosin and Carvedilol as a Potential Therapeutic for Hepatic Fibrosis.
作者信息
Paik Yong-Han
机构信息
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,Seoul, Korea.
Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
出版信息
Gut Liver. 2016 Jan;10(1):10-1. doi: 10.5009/gnl15576.
Abstract
摘要
相似文献
1
Reappraisal of Antihypertensive Medicine Doxazosin and Carvedilol as a Potential Therapeutic for Hepatic Fibrosis.
Gut Liver. 2016 Jan;10(1):10-1. doi: 10.5009/gnl15576.
2
Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth Factor β Secretion.
Gut Liver. 2016 Jan;10(1):101-8. doi: 10.5009/gnl14459.
3
[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine].
Wien Med Wochenschr. 1995;145(15-16):373-82.
4
Adenoviral‑bone morphogenetic protein‑7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model.
Mol Med Rep. 2017 Dec;16(6):9431-9440. doi: 10.3892/mmr.2017.7785. Epub 2017 Oct 12.
5
Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
Circulation. 2008 Jul 1;118(1):42-8. doi: 10.1161/CIRCULATIONAHA.107.737957. Epub 2008 Jun 16.
6
Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol.
Coron Artery Dis. 1994 Nov;5(11):909-18.
7
Long-term organ protection by doxazosin and/or quinapril as antihypertensive therapy.
J Nephrol. 2006 Sep-Oct;19(5):588-98.
8
Clinical ease of using doxazosin in BPH patients with and without hypertension.
Prostate Cancer Prostatic Dis. 2005;8(2):152-7. doi: 10.1038/sj.pcan.4500787.
9
Doxazosin in the current treatment of hypertension.
Expert Opin Pharmacother. 2008 Mar;9(4):625-33. doi: 10.1517/14656566.9.4.625.
引用本文的文献
1
Curcumin and /-Adrenergic Antagonists Cotreatment Reverse Liver Cirrhosis in Hamsters: Participation of Nrf-2 and NF-B.
J Immunol Res. 2019 Apr 30;2019:3019794. doi: 10.1155/2019/3019794. eCollection 2019.
本文引用的文献
1
Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth Factor β Secretion.
Gut Liver. 2016 Jan;10(1):101-8. doi: 10.5009/gnl14459.
2
Antifibrotic therapies in the liver.
Semin Liver Dis. 2015 May;35(2):184-98. doi: 10.1055/s-0035-1550055. Epub 2015 May 14.
3
Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation.
Gut. 2015 Jul;64(7):1111-9. doi: 10.1136/gutjnl-2013-306502. Epub 2014 Oct 3.
4
Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.
Gastroenterology. 2014 Jun;146(7):1680-90.e1. doi: 10.1053/j.gastro.2014.03.005. Epub 2014 Mar 12.
5
Role of NADPH oxidases in liver fibrosis.
Antioxid Redox Signal. 2014 Jun 10;20(17):2854-72. doi: 10.1089/ars.2013.5619. Epub 2014 Jan 24.
6
Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells.
PLoS One. 2013 Sep 3;8(9):e72928. doi: 10.1371/journal.pone.0072928. eCollection 2013.
7
Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study.
Liver Int. 2012 Jul;32(6):977-87. doi: 10.1111/j.1478-3231.2012.02774.x. Epub 2012 Feb 26.
8
Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells.
Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G877-84. doi: 10.1152/ajpgi.00537.2005. Epub 2006 Jun 15.
9
Hepatic fibrogenesis requires sympathetic neurotransmitters.
Gut. 2004 Mar;53(3):438-45. doi: 10.1136/gut.2003.026658.
10
Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.
Hepatology. 2002 Dec;36(6):1367-73. doi: 10.1053/jhep.2002.36947.
Zotero 插件